<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        302-186-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DANDAXA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        192
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>dandaxa </strong>is a treatment for adult men with erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. <strong>dandaxa</strong> has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity.</p><p><strong>dandaxa </strong>contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Following sexual stimulation <strong>dandaxa </strong>works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. <strong>dandaxa</strong> will not help you if you do not have erectile dysfunction.</p><p>It is important to note that <strong>dandaxa </strong>does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take dandaxa if you:</strong></p><p>-&nbsp;&nbsp; Are allergic to tadalafil or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp; Are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). Tadalafil has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.</p><p>-&nbsp;&nbsp; Have serious heart disease or recently had a heart attack within the last 90 days.</p><p>-&nbsp;&nbsp; Recently had a stroke within the last 6 months.</p><p>-&nbsp;&nbsp; Have low blood pressure or uncontrolled high blood pressure.</p><p>-&nbsp;&nbsp; Ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.</p><p>-&nbsp;&nbsp; Are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots).</p><p>PDE5 inhibitors, such as tadalafil, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking <strong>dandaxa</strong>.</p><p>Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.</p><p><strong>Before taking the tablets, tell your doctor if you have:</strong></p><p>-&nbsp;&nbsp; Sickle cell anaemia (an abnormality of red blood cells).</p><p>-&nbsp;&nbsp; Multiple myeloma (cancer of the bone marrow).</p><p>-&nbsp;&nbsp; leukaemia (cancer of the blood cells).</p><p>-&nbsp;&nbsp; Any deformation of your penis.</p><p>-&nbsp;&nbsp; A serious liver problem.</p><p>-&nbsp;&nbsp; A severe kidney problem.</p><p>It is not known if tadalafil is effective in patients who have had:</p><p>-&nbsp;&nbsp; Pelvic surgery.</p><p>-&nbsp;&nbsp; Removal of all or part of the prostate gland in which nerves of the prostate are cut (radical non nerve sparing prostatectomy).</p><p>If you experience sudden decrease or loss of vision, stop taking <strong>dandaxa </strong>and contact your doctor immediately.</p><p>Decreased or sudden hearing loss has been noted in some patients taking tadalafil. Although it is not known if the event is directly related to tadalafil, if you experience decreased or sudden hearing loss, stop taking <strong>dandaxa</strong> and contact your doctor immediately.</p><p><strong>dandaxa</strong> is not intended for use by women.</p><p><strong><u>Children and adolescents</u></strong></p><p><strong>dandaxa</strong> is not intended for use by children and adolescents under the age of 18.</p><p><strong>Other medicines and dandaxa </strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines</p><p>Do not take <strong>dandaxa</strong> if you are already taking nitrates.</p><p>Some medicines may be affected by <strong>dandaxa </strong>or they may affect how well <strong>dandaxa </strong>will work. Tell your doctor or pharmacist if you are already taking:</p><p>-&nbsp;&nbsp; An alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp; Other medicines to treat high blood pressure.</p><p>-&nbsp;&nbsp; Riociguat.</p><p>-&nbsp;&nbsp; A 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp; Medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for treatment of AIDS or HIV infection.</p><p>-&nbsp;&nbsp; Phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).</p><p>-&nbsp;&nbsp; Rifampicin, erythromycin, clarithromycin or itraconazole.</p><p>-&nbsp;&nbsp; Other treatments for erectile dysfunction.</p><p><strong>dandaxa</strong> <strong>with drink and alcohol</strong></p><p>Information on the effect of alcohol is in section 3. Grapefruit juice may affect how well <strong>dandaxa </strong>will work and should be taken with caution. Talk to your doctor for further information.</p><p><strong>Fertility</strong></p><p>When dogs were treated there was reduced sperm development in the testes. A reduction in sperm was seen in some men. These effects are unlikely to lead to a lack of fertility.</p><p><strong>Driving and using machines</strong></p><p>Some men taking tadalafil in clinical studies have reported dizziness. Check carefully how you react to the tablets before driving or using machines.</p><p><strong>dandaxa contains lactose</strong></p><p>If you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>dandaxa </strong>tablets are for oral use in men only. Swallow the tablet whole with some water. The tablets can be taken with or without food.</p><p><strong>The recommended starting dose </strong>is one 10mg tablet before sexual activity. However, you have been given the dose of one 20mg tablet as your doctor has decided that the recommended dose of 10mg is too weak.</p><p>You may take a <strong>dandaxa</strong> tablet at least 30 minutes before sexual activity.</p><p><strong>dandaxa</strong> may still be effective up to 36 hours after taking the tablet.</p><p>Do not take <strong>dandaxa </strong>more than once a day. <strong>dandaxa </strong>is intended for use prior to anticipated sexual activity and is not recommended for continuous daily use.</p><p>It is important to note that <strong>dandaxa </strong>does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p><p>Drinking alcohol may affect your ability to get an erection and may temporarily lower your blood pressure. If you have taken or are planning to take <strong>dandaxa</strong>, avoid excessive drinking (blood alcohol level of 0.08 % or greater), since this may increase the risk of dizziness when standing up.</p><p><strong>If you take more dandaxa</strong> <strong>than you should</strong></p><p>Contact your doctor. You may experience side effects described in section 4.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.</p><p><strong>If you experience any of the following side effects stop using the medicine and seek medical help immediately:</strong></p><p>-&nbsp;&nbsp; Allergic reactions including rashes (frequency uncommon).</p><p>-&nbsp;&nbsp; Chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Priapism, prolonged and possibly painful erection after taking tadalafil (frequency rare). If you have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.</p><p>-&nbsp;&nbsp; Sudden loss of vision (frequency rare).</p><p>Other side effects have been reported:</p><p><strong>Common </strong>(seen in 1 to 10 in every 100 patients)</p><p>-&nbsp;&nbsp; Headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, and indigestion.<strong> </strong></p><p><strong>Uncommon </strong>(seen in 1 to 10 in every 1,000 patients)</p><p>-&nbsp;&nbsp; Dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and feeling tired<strong> </strong></p><p><strong>Rare </strong>(seen in 1 to 10 in every 10,000 patients)</p><p>-&nbsp;&nbsp; Fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing, hives (itchy red welts on the surface of the skin), penile bleeding, presence of blood in semen and increased sweating</p><p>Heart attack and stroke have also been reported rarely in men taking tadalafil. Most of these men had known heart problems before taking this medicine.</p><p>Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.</p><p><strong>Some additional rare side effects </strong>have been reported in men taking tadalafil that were not seen in clinical trials. These include:</p><p>-&nbsp;&nbsp; Migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.</p><p>The side effect dizziness has been reported more frequently in men over 75 years of age taking tadalafil. Diarrhoea has been reported more frequently in men over 65 years of age taking tadalafil.</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>You can also report side effects directly via:</p><p><strong>● Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>SFDA Call Centre: 19999</strong></p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> https://ade.sfda.gov.sa/</p><p><strong>● Other GCC States:</strong></p><p>&ndash; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister.</p><p>-&nbsp;&nbsp; The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp; Store below 30&deg;C.</p><p>-&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What dandaxa contains</strong></p><p>The <strong>active </strong>substance is tadalafil. Each film-coated tablet contains 20 mg of tadalafil.</p><p>The other ingredients are: Lactose monohydrate, microcrystalline cellulose, sodium lauryl sulphate, hydroxyl propyl cellulose, croscarmellose sodium, magnesium stearate, hypromellose, triacetin, talcfine powder, titanium dioxide and iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
– Packs of 1 film-coated tablet (one blister only) each.
– Packs of 4 film-coated tablets (one blister only) each.
– Packs of 12 film-coated tablets (3 blisters, each blister contains 4 film-coated tablets) each
 



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Gulf Pharmaceutical Industries <strong>(Julphar)</strong>,</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                30/12/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تعد أقراص <strong>داندكسا </strong>علاج لحالات عجز انتصاب القضيب لدى الذكور البالغين. وتحدث هذه الحالة عندما لا يستطيع الرجل الحصول أو الحفاظ على قضيب ذو صلابة وانتصاب بصورة مناسبة للقيام بالعلاقة الجنسية.</p><p dir="RTL">لقد تبين أن <strong>داندكسا </strong>يحدث تحسن ملحوظ في القدرة على الحصول على قضيب ذو صلابة وانتصاب بصورة مناسبة للقيام بالعلاقة الجنسية.&nbsp;&nbsp;</p><p dir="RTL">تحتوي أقراص <strong>داندكسا </strong>&nbsp;على المادة الفعالة تادالافيل والتي تنتمي إلى مجموعة الأدوية المعروفة بالأدوية المثبطة لإنزيم فوسفو داي إستريز من النوع الخامس.</p><p dir="RTL">بعد حصول الإثارة الجنسية، فإن <strong>داندكسا</strong> يساعد على ارتخاء الأوعية الدموية في القضيب، مما يسمح بتدفق الدم إلى القضيب. يؤدي هذا الأمر بدوره إلى تحسين الانتصاب. لن يساعدك <strong>داندكسا</strong> في شيء إذا لم يكن لديك عجز في انتصاب القضيب.</p><p dir="RTL">إنه من المهم الملاحظة بأن <strong>داندكسا </strong>لا يقوم بأي دور إذا لم تحصل الإثارة الجنسية. سوف تحتاج أنت والشريك الآخر للدخول في مداعبة تماماً كما تفعل لو كنت لا تأخذ الدواء لعلاج ضعف الانتصاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه تادالافيل أو تجاه أياً من المكونات الأخرى لهذا الدواء)المذكورة في الفقرة رقم 6(.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتناول النترات العضوية بأي شكل من الأشكال أو أي مادة مانحة لعنصر أكسيد النيتريك مثل نترات الأميل. تستخدم هذه المجموعة من الأدوية (النترات) لعلاج الذبحة الصدرية (&quot;ألم الصدر&quot;). قد يتسبب تادالافيل في زيادة الآثار الجانبية المترتبة على هذه الأدوية.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تتناول أي شكل من أشكال النترات أو إذا كان لديك أدنى شك بذلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض قلبية خطيرة أو تعرضت مؤخراً لنوبة قلبية خلال 90 يوم الماضية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; في حال تعرضك مؤخراً لسكتة دماغية خلال 6 أشهر الماضية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض ضغط الدم أو ارتفاع في ضغط الدم لم تتم السيطرة عليه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت فيما مضى لفقدان الرؤية بسبب وجود اعتلال في العصب البصري الأمامي غير الشرياني الناتج عن نقص التروية الدموية لعصب العين الأمامي، وتعرف هذه الحالة &quot;جلطة العين&quot;.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تتناول دواء يعرف باسم ريوسيجوت. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الرئتين)&nbsp; وارتفاع ضغط الدم الرئوي الانسدادي التجلطي المزمن (ارتفاع ضغط الدم في الرئتين الذي يحدث بصورة ثانوية لتجلط الدم).</p><p dir="RTL">إن الأدوية المثبطة لإنزيم فوسفو داي إستريز من النوع الخامس، على سبيل المثال تادالافيل وجد أنها تزيد من التأثير الخافض لضغط الدم لهذا الدواء. يرجى منك إخبار طبيبك المعالج إذا كنت تتناول دواء ريوسيجوت أو إذا كنت غير متأكد من ذلك.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يجب عليك إخبار طبيبك المعالج قبل تناول<strong> داندكسا</strong>.</p><p dir="RTL">يجب أن تدرك بأن العلاقة الجنسية قد تحمل مخاطر ممكنة للمرضى الذين يعانون من مرض في القلب لأنه يضع ضغطاً إضافياً على القلب. لذا يجب عليك إخبار طبيبك المعالج إذا كنت تعاني من اضطراب في القلب.</p><p dir="RTL">&nbsp;<strong>يجب عليك إخبار طبيبك المعالج قبل تناول أقراص داندكسا &nbsp;في الحالات التالية: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فقر الدم المنجلي (وجود تغير غير طبيعي في شكل خلايا الدم الحمراء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الورم النخاعي المتعدد (سرطان نخاع العظم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اللوكيميا (سرطان الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; في حال وجود أي تشوه في القضيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب خطير في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب خطير في الكلى</p><p dir="RTL">لم يعرف حتى الآن مدى فعالية تادالافيل في المرضى الذين قد خضعوا مسبقاً لإحدى الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عملية جراحية في الحوض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عملية إزالة كل أو جزء من غدة البروستاتا التي يتم فيها قطع أعصاب البروستاتا (عملية استئصال غدة البروستاتا الجذرية مع إزالة الأعصاب).</p><p dir="RTL">يرجى منك التوقف عن تناول <strong>داندكسا</strong> واستشارة طبيبك المعالج على الفور، في حال تعرضك لنقص أو فقدان للرؤية بصورة مفاجئة.</p><p dir="RTL">لوحظ حدوث ضعف أو فقدان مفاجئ في السمع لدى بعض المرضى الذين تلقوا تادالافيل. على الرغم من أنه من غير المعروف ما إذا كان هذا الحدث مرتبطاً بشكل مباشر بتادالافيل، يرجى منك التوقف عن تناول <strong>داندكسا</strong> والتواصل مع طبيبك المعالج على الفور، في حال تعرضك لحدوث ضعف أو فقدان مفاجئ في السمع.</p><p dir="RTL">إن <strong>داندكسا</strong><strong> </strong>غير معد للاستعمال من قبل النساء.</p><p dir="RTL"><strong><u>الأطفال والمراهقين</u></strong></p><p dir="RTL">إن <strong>داندكسا &nbsp;</strong>غير معد للاستعمال من قبل الأطفال والمراهقين بعمر أقل من 18 سنة.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع داندكسا </strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أية أدوية أخرى. لا يجب تناول أقراص <strong>داندكسا &nbsp;</strong>إذا كنت بالفعل تتناول النترات.</p><p dir="RTL">قد تتأثر بعض الأدوية بمفعول <strong>داندكسا، </strong>كما قد تؤثر بعض الأدوية على آلية عمل <strong>داندكسا </strong>. يجب عليك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>داندكسا </strong>إذا كنت تتناول بالفعل أحد الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; غالقات مستقبلات ألفا (أدوية تستخدم لعلاج ارتفاع ضغط الدم أو أعراض الجهاز البولي المصاحبة لتضخم البروستاتا الحميد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تستخدم لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ريوسيجوات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إنزيم 5- ألفا المُختزل (يستخدم لعلاج تضخم البروستاتا الحميد الناتج عن فرط التنسج).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل أقراص كيتوكونازول (لعلاج العدوى الفطرية) ومثبطات إنزيم البروتيز التي تستخدم لعلاج الإيدز أو عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال، فينيتوين وكاربامازيبين (أدوية مضادة للتشنجات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، إيرثرومايسين، كلاريثرومايسين أو إتراكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تستخدم لعلاج ضعف الانتصاب</p><p dir="RTL"><strong>تناول داندكسا &nbsp;مع الشراب والكحول</strong></p><p dir="RTL">إن المعلومات المتوفرة حول تأثير الكحول مذكورة في البند رقم 3. قد يؤثر عصير الجريب فروت على آلية عمل<strong> </strong><strong>داندكسا</strong>، لذا يجب تناوله بحذر. يرجى منك استشارة طبيبك المعالج للحصول على المزيد من المعلومات.</p><p dir="RTL"><strong>التأثير على الخصوبة</strong></p><p dir="RTL">لقد لوحظ حدوث نقص في نمو الحيوانات المنوية الموجودة في الخصية لدى ذكور الكلاب عند إجراء التجارب باستعمال تادالافيل. كما لوحظ حدوث نقص في الحيوانات المنوية لدى بعض الرجال الذين تلقوا العلاج، ولكن من غير المرجح أن تؤدي هذه التأثيرات إلى ضعف الخصوبة في الإنسان.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سجل حدوث دوخة في التجارب السريرية عند تناول تادالافيل<strong> </strong>من قبل بعض الرجال. يجب التحقق بعناية عن مدى استجابة جسمك لهذا الدواء قبل القيادة واستخدام الآلات.</p><p dir="RTL"><strong>يحتوي داندكسا على لاكتوز</strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء إذا كنت تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائماً تناول <strong>داندكسا</strong> بدقة وفقاً لتعليمات طبيبك المعالج، كما يجب استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من الجرعات.</p><p dir="RTL">إن أقراص<strong> داندكسا </strong>&nbsp;معدة للاستعمال من قبل الرجال فقط عن طريق الفم. ابلع الأقراص كاملة مع بعض من الماء.</p><p dir="RTL">من الممكن تناول الأقراص مع الطعام أو بدونه.</p><p dir="RTL"><strong>تبلغ</strong> <strong>الجرعة الأولية الموصى بها </strong>قرص واحد 10 ملغم يتم تناولها قبل العلاقة الجنسية. ولكن، في حال قرر الطبيب المعالج بأن هذه الجرعة الأولية الموصى بها ضعيفة جداً، عندئذٍ ستعطى لك جرعة أكبر مقدارها 20 ملغم.</p><p dir="RTL">يجب أن تتناول<strong> داندكسا</strong> قبل العلاقة الجنسية بمدة لا تقل عن نصف ساعة.</p><p dir="RTL">قد يستمر مفعول <strong>داندكسا </strong>لفترة تصل إلى 36 ساعة بعد تناول القرص.</p><p dir="RTL">يجب عدم تناول <strong>داندكسا </strong>أكثر من مرة واحدة في اليوم. إن<strong> داندكسا &nbsp;</strong>معد للاستعمال قبل العلاقة الجنسية المشتركة ولا يوصى بإعطائه بشكل يومي ومستمر.</p><p dir="RTL">من المهم الملاحظة بأن <strong>داندكسا </strong>&nbsp;لن يكون له أي مفعول إذا لم تحصل الإثارة الجنسية. سوف تحتاج أنت والشريك الآخر للدخول في مداعبة تماماً كما تفعل لو كنت لا تأخذ الدواء لعلاج ضعف الانتصاب.</p><p dir="RTL">قد يؤثر تناول الكحول على القدرة على الانتصاب، كما أنه قد يؤدي إلى هبوط ضغط الدم بصورة مؤقتة. إذا كنت تتناول أقراص <strong>داندكسا </strong>&nbsp;أو إذا كنت تنوي تناولها، فإنه يجب عليك تجنب التناول المفرط للكحول (مستوى الكحول في الدم 0,08٪ أو أكبر)، حيث أن هذا قد يزيد من خطر حدوث الدوخة عند الوقوف.</p><p dir="RTL"><strong>إذا تناولت داندكسا بجرعة أكبر مما يجب</strong></p><p dir="RTL">يجب عليك استشارة طبيبك المعالج في حال تناولك جرعة أكبر من المقدار الموصى به. قد تتعرض لتأثيرات جانبية لهذا الدواء مذكورة في البند رقم 4.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول</strong><strong> </strong><strong>كيفية استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي <strong>داندكسا </strong>&nbsp;إلى حدوث تأثيرات جانبية، ولكن قد لا تحدث لكل شخص. إن هذه التأثيرات عادة ما تتراوح في شدتها من خفيفة إلى متوسطة.</p><p dir="RTL"><strong>إذا تعرضت لأي من التأثيرات الجانبية التالية فإنه يجب عليك التوقف عن تناول الدواء وطلب المشورة الطبية على الفور: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تفاعلات الحساسية بما في ذلك الطفح الجلدي (معدل التكرار:غير شائعة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ألم في الصدر- لا تستخدم النترات ولكن اطلب المشورة الطبية على الفور (معدل التكرار: غير شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; قساح، حدوث الانتصاب لفترة طويلة قد يكون مصحوباً بألم بعد تناول<strong> </strong>تادالافيل (معدل التكرار: نادر). إذا كنت تعاني مثل هذه الحالة والتي تستغرق فترة أكثر من 4 ساعات بصورة مستمرة، فإنه يجب عليك الاتصال بالطبيب المعالج على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; فقدان مفاجئ للرؤية (معدل التكرار: نادر).</p><p dir="RTL">كما سجل حدوث تأثيرات جانبية أخرى:</p><p dir="RTL"><strong>شائعة </strong>(شوهدت في 1-10من المرضى في كل 100 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; صداع، ألم في الظهر، آلام في العضلات، ألم في الذراعين والقدمين، توهج (احمرار) في الوجه، احتقان الأنف، وعسر الهضم.</p><p dir="RTL"><strong>غير شائعة </strong>(شوهدت في 1-10من المرضى في كل 1000 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; &nbsp;دوخة، ألم في المعدة، الشعور بالإعياء (غثيان)، التوعك (تقيؤ)،الارتجاع، عدم وضوح الرؤية، ألم في العين، صعوبة في التنفس، وجود دم في البول، الشعور بنبض قوي للقلب، تسارع نبضات القلب، ارتفاع ضغط الدم، انخفاض ضغط الدم، نزيف من الأنف، طنين في الأذنين، تورم اليدين، القدمين أو الكاحلين والشعور بالتعب.</p><p dir="RTL"><strong>نادرة </strong>(شوهدت في 1-10 من المرضى في كل 10000 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إغماء، نوبات صرع، فقدان الذاكرة، تورم في جفني العينين، احمرار العين، حدوث نقص أو فقدان مفاجئ للسمع، طفح جلدي على شكل خلايا النحل (بقع حمراء مصحوبة بحكة على سطح الجلد)، نزيف من القضيب، وجود دم في السائل المنوي وزيادة التعرق.</p><p dir="RTL">وسجل بصورة نادرة حدوث نوبة قلبية وسكتة دماغية لدى المرضى الرجال الذين تناولوا تادالافيل، وكان معظمهم قد سبق وأن عانوا من مشاكل معروفة في القلب قبل تناول هذا الدواء.</p><p dir="RTL">وسجل أيضاً بصورة نادرة حدوث نقص أو فقدان للرؤية بصورة جزئية أو مؤقتة أو دائمة في إحدى العينين أو كلتيهما.</p><p dir="RTL">كما وردت بعض التقارير حول حدوث <strong>بعض التأثيرات الجانبية الأخرى النادرة </strong>لدى المرضى الرجال الذين تناولوا تادالافيل ، والتي لم تظهر في التجارب السريرية. وتتضمن هذه التأثيرات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي (شقيقة)، تورم في الوجه، تفاعل تحسسي خطير الذي يسبب تورم الوجه أو الحلق، طفح جلدي خطير، وبعض الاضطرابات التي تؤثر على تدفق الدم للعينين، عدم انتظام نبضات القلب، ذبحة صدرية وموت مفاجئ للقلب.</p><p dir="RTL">إن التأثيرات الجانبية كالدوخة قد سجلت بصورة أكثر تكراراً لدى المرضى الرجال بعمر أكبر من<br />&nbsp;75 عاماً وتناولوا تادالافيل. إن التأثيرات الجانبية كالإسهال قد سجلت بصورة أكثر تكراراً لدى المرضى الرجال بعمر أكبر من 65 عاماً وتناولوا تادالافيل.</p><p dir="RTL"><strong><u>للإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>● </strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL"><strong>المركز</strong><strong> </strong><strong>الوطني</strong><strong> </strong><strong>للتيقظ</strong><strong> </strong><strong>الدوائي</strong><strong>:</strong></p><p dir="RTL"><strong>مركز</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>الموحد</strong>19999<strong> :</strong></p><p dir="RTL"><strong>البريد</strong><strong> </strong><strong>الإلكتروني</strong>npc.drug@sfda.gov.sa <strong>:</strong></p><p dir="RTL"><strong>الموقع</strong><strong> </strong><strong>الإلكتروني</strong><strong> : </strong>/ https://ade.sfda.gov.sa</p><p dir="RTL">● <strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">- الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&ordm;م.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تادالافيل. يحتوي كل قرص مكسو على 20 ملغم من تادالافيل.</p><p dir="RTL">المواد الأخرى: لاكتوز أحادي الهيدرات، بلورات السليلوز متناهية الصغر، سلفات لوريل الصوديوم، هيدروكسي بروبيل السليلوز، كروس كارميلوز الصوديوم، استيارات المغنيسيوم، هيبروميلوز، تراي أسيتين، مسحوق التلك الناعم، ثنائي أكسيد التيتانيوم وأكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-عبوات تحتوي كلاً منها على 1 قرص مكسو (شريط واحد فقط).</p><p dir="RTL">&ndash; عبوات تحتوي كلاً منها على 4 أقراص مكسوة (شريط واحد فقط).</p><p dir="RTL">&ndash; عبوات تحتوي كلاً منها على 12 قرصاً مكسواً (ثلاثة أشرطة، يحتوي كل شريط على 4 أقراص مكسوة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الخليج للصناعات الدوائية (<strong>جلفار</strong>)،</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2020/12/30 م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dandaxa 20mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
Item no.	Material Name	Scale (mg/Tablet)
		
	Active Ingredient:	
1.		Tadalafil * 	20.000
		
	Inactive Ingredients:	
	For Core:	
1.		Lactose monohydrate 	235.35
2.		Microcrystalline cellulose 	50.00
3.		Sodium lauryl sulphate 	0.80
4.		Hydroxy propyl cellulose 	3.25
5.		Croscarmellose sodium 	9.60
6.		Magnesium stearate 	1.00
7.		Purified water **	q.s. 
		
	For Coating:	
1.		Hypromellose 	4.00
2.		Triacetin 	1.30
3.		Talc fine powder 	1.65
4.		Titanium dioxide 	1.20
5.		Lactose monohydrate 	1.40
6.		Iron oxide yellow 	0.45
7.		Purified water **	q.s. 
8.		Absolute alcohol **	q.s. 

Average weight of coated tablet is: 330mg ± 5% (313.50mg – 346.50mg)
Note:
*	Based on Tadalafil assay, the quantity of lactose monohydrate may be varied to keep core tablet weight 320mg.
**	This will not appear in the final product.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
Description: Yellow coloured, diamond shaped, biconvex film-coated tablets 
Marking: 
Face one: Embossed with “20”
Face two: Plain


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dandaxa </strong>is indicated for the treatment of erectile dysfunction in adult males.</p><p>In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required.</p><p>Tadalafil is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong>Erectile dysfunction in adult Men</strong></p><p>In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food.</p><p>In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual activity.</p><p>The maximum dose frequency is once per day.</p><p>Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use.</p><p>In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician&#39;s judgement.</p><p>In these patients, the recommended dose is 5mg taken once a day at approximately the same time of day. The dose may be decreased to 2.5mg once a day based on individual tolerability.</p><p>The appropriateness of continued use of the daily regimen should be reassessed periodically.</p><p><strong><u>Special Populations</u></strong></p><p><strong>Elderly Men</strong></p><p>Dose adjustments are not required in elderly patients.</p><p><strong>Men with Renal Impairment</strong></p><p>Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with severe renal impairment, 10 mg is the maximum recommended dose.</p><p><strong>Men with Hepatic Impairment </strong></p><p>For the treatment of erectile dysfunction using on-demand&nbsp; tadalafil the recommended dose of tadalafil is 10 mg taken prior to anticipated sexual activity and with or without food. There is limited clinical data on the safety of tadalafil in patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10mg of tadalafil to patients with hepatic impairment.</p><p>Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician (see sections 4.4 and 5.2).</p><p><strong>Men with Diabetes</strong></p><p>Dose adjustments are not required in diabetic patients.</p><p><strong>Paediatric population</strong></p><p>There is no relevant use of tadalafil in the paediatric population with regard to the treatment of erectile dysfunction.</p><p><strong><u>Method of administration</u></strong></p><p><strong>Dandaxa </strong>film-coated tablets are for oral use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated (see section 4.5).
Tadalafil must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.

The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
	patients with myocardial infarction within the last 90 days,
	patients with unstable angina or angina occurring during sexual intercourse,
	patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,
	patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension,
	patients with a stroke within the last 6 months. 
Tadalafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Before treatment with tadalafil</u></strong></p><p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before pharmacological treatment is considered.</p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1) and as such potentiates the hypotensive effect of nitrates (see section 4.3).</p><p>The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an appropriate medical assessment. It is not known if tadalafil is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy.</p><p><strong><u>Cardiovascular</u></strong></p><p>Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations and tachycardia, have been reported either post marketing and/or in clinical trials. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to tadalafil, to sexual activity, or to a combination of these or other factors.</p><p>In patients who are taking alpha<sub>1</sub>&nbsp;blockers, concomitant administration of tadalafil may lead to symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and doxazosin is not recommended.</p><p><strong><u>Vision</u></strong></p><p>Visual defects and cases of NAION have been reported in connection with the intake of tadalafil and other PDE5 inhibitors. Analyses of observational data suggest an increased risk of acute NAION in men with erectile dysfunction following exposure to tadalafil or other PDE5 inhibitors. As this may be relevant for all patients exposed to tadalafil, the patient should be advised that in case of sudden visual defect, he should stop taking tadalafil and consult a physician immediately (see section 4.3).</p><p><strong><u>Decreased or sudden hearing loss</u></strong></p><p>Cases of sudden hearing loss have been reported after the use of tadalafil. Although other risk factors were present in some cases (such as age, diabetes, hypertension and previous hearing loss history) patients should be advised to stop taking tadalafil and seek prompt medical attention in the event of sudden decrease or loss of hearing.</p><p>&nbsp;</p><p><strong><u>Hepatic impairment (tadalafil 10 mg and 20 mg)</u></strong></p><p>There is limited clinical data on the safety of single-dose administration of tadalafil in patients with severe hepatic insufficiency (Child-Pugh Class C). If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><strong><u>Priapism and anatomical deformation of the penis </u></strong></p><p>Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.</p><p>Tadalafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p><strong><u>Use with CYP3A4 inhibitors</u></strong></p><p>Caution should be exercised when prescribing tadalafil to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).</p><p><strong><u>Tadalafil and other treatments for erectile dysfunction </u></strong></p><p>The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. The patients should be informed not to take tadalafil in such combinations.</p><p><strong><u>Lactose</u></strong></p><p><strong>Dandaxa </strong>contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out.</p><p><strong><u>Effects of Other Substances on Tadalafil</u></strong></p><p><strong>Cytochrome P450 inhibitors</strong></p><p>Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and C<sub>max</sub>&nbsp;by 15%, relative to the AUC and C<sub>max</sub>&nbsp;values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg) exposure (AUC) 4-fold and C<sub>max</sub>&nbsp;by 22%. Ritonavir, a protease inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fold with no change in C<sub>max</sub>. Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would be expected to increase plasma concentrations of tadalafil (see section 4.4). Consequently, the incidence of the adverse reactions listed in section 4.8 might be increased.</p><p><strong>Transporters</strong></p><p>The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known. Therefore, there is the potential of drug interactions mediated by inhibition of transporters.</p><p><strong>Cytochrome P450 inducers</strong></p><p>A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.</p><p>&nbsp;</p><p><strong><u>Effects of Tadalafil on Other Medicinal Products</u></strong></p><p><strong>Nitrates</strong></p><p>In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of nitrates. Therefore, administration of tadalafil to patients who are using any form of organic nitrate is contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of tadalafil (2.5 mg- 20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of tadalafil before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate haemodynamic monitoring.</p><p><strong>Anti-hypertensives (including calcium channel blockers)</strong></p><p>The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this combination is not recommended (see section 4.4).</p><p>In interaction studies performed in a limited number of healthy volunteers, these effects were not reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and progressively adjusted.</p><p>In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products were studied, including calcium-channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg, except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology study, tadalafil (20 mg) was studied in combination with up to 4 classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of blood pressure control. In this regard, study subjects whose blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy subjects. In study subjects whose blood pressure was not controlled, the reduction was greater, although this reduction was not associated with hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alpha-blockers - see above) is, in general, minor and not likely to be clinically relevant. Analysis of Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products. However, appropriate clinical advice should be given to patients regarding a possible decrease in blood pressure when they are treated with antihypertensive medicinal products.</p><p><strong>Riociguat</strong></p><p>Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is contraindicated (see section 4.3).</p><p><strong>5- alpha reductase inhibitors</strong></p><p>In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified. However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil is co-administered with 5-ARIs.</p><p><strong>CYP1A2 substrates (e.g. theophylline)</strong></p><p>When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is minor and was of no clinical significance in this study, it should be considered when co-administering these medicinal products.</p><p><strong>Ethinylestradiol and terbutaline</strong></p><p>Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, although the clinical consequence of this is uncertain.</p><p><strong>Alcohol</strong></p><p>Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by co-administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximise the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7 g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).</p><p><strong>Cytochrome P450 metabolised medicinal products</strong></p><p>Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.</p><p><strong>CYP2C9 substrates (e.g. R-warfarin)</strong></p><p>Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin.</p><p><strong>Aspirin</strong></p><p>Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid.</p><p><strong>Antidiabetic medicinal products</strong></p><p>Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil is not indicated for use by women.</p><p><strong><u>Pregnancy</u></strong></p><p>There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy<strong><em>,&nbsp;</em></strong>embryonal/foetal development, parturition or postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of tadalafil during pregnancy.</p><p><strong><u>Breastfeeding</u></strong></p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A risk to the suckling child cannot be excluded. Tadalafil should not be used during breast feeding.</p><p><strong><u>Fertility</u></strong></p><p>Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men (see sections 5.1 and 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil has negligible influence on the ability to drive or use machines. Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to tadalafil before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with tadalafil once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.</p><p><strong><u>Tabulated summary of adverse reactions</u></strong></p><p>The table below lists the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 8022 patients on tadalafil and 4422 patients on placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia.</p><p>Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:560px"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td><td style="vertical-align:top"><p>Angioedema<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Stroke<sup>1&nbsp;</sup>(including haemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures<sup>2</sup>, Transient amnesia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blurred vision, Sensations described as eye pain</p></td><td style="vertical-align:top"><p>Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Sudden hearing loss</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Cardiac disorders<sup>1</sup></em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Myocardial infarction, Unstable angina pectoris<sup>2</sup>, Ventricular arrhythmia<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension<sup>3</sup>, Hypertension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, Stevens-Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup>, Hyperhydrosis (sweating)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Back pain, Myalgia, Pain in extremity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prolonged erections</p></td><td style="vertical-align:top"><p>Priapism, Penile haemorrhage, Haematospermia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Chest pain<sup>1,&nbsp;</sup>Peripheral oedema, Fatigue</p></td><td style="vertical-align:top"><p>Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></p></td></tr></tbody></table><p>(1) Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).</p><p>(2) Post marketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials.</p><p>(3) More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products.</p><p><strong><u>Description of selected adverse reactions</u></strong></p><p>A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities were not associated with adverse reactions.</p><p><strong><u>Other special populations</u></strong></p><p>Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials with tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported more frequently in patients over 65 years of age. In clinical trials with tadalafil 5 mg taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age.</p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses.</p><p>In cases of overdose, standard supportive measures should be adopted, as required. Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Urologicals, Drugs used in erectile dysfunction. ATC code: G04BE08.</p><p><strong><u>Mechanism of action</u></strong></p><p>Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in the absence of sexual stimulation.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Studies&nbsp;<em>in vitro</em>&nbsp;have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for phototransduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through PDE10.</p><p><strong>Clinical efficacy and safety</strong></p><p>Tadalafil administered to healthy subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6mmHg, respectively), and no significant change in heart rate.</p><p>In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of changes in colour vision were rare (&lt;0.1%).</p><p>Three studies were conducted in men to assess the potential effect on spermatogenesis of tadalafil 10mg (one 6-month study) and 20mg (one 6-month and one 9-month study) administered daily. In two of these studies decreases were observed in sperm count and concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not associated with changes in other parameters, such as motility, morphology, and FSH.</p><p><strong>Erectile dysfunction</strong></p><p>Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to tadalafil on demand. Tadalafil demonstrated statistically significant improvement in erectile function and the ability to have successful sexual intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful intercourse compared to placebo as early as 16 minutes following dosing.</p><p>In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg (flexible-dose, on demand) of 48% as compared to 17% with placebo.</p><p>Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients, including patients with erectile dysfunction of various severities (mild, moderate, severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of patients reported that tadalafil improved their erections as compared to 35% with placebo. Also, patients with erectile dysfunction in all severity categories reported improved erections whilst taking tadalafil (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts were successful in tadalafil-treated patients as compared to 32% with placebo.</p><p>For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were initially conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile dysfunction of various severities (mild, moderate, severe) and etiologies. In the two primary efficacy studies of general populations, the mean per-subject proportion of successful intercourse attempts were 57 and 67% on tadalafil 5mg, 50% on tadalafil 2.5mg as compared to 31 and 37% with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46% on tadalafil 5mg and 2.5mg, respectively, as compared to 28% with placebo. Most patients in these three studies were responders to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217 patients who were treatment-naive to PDE5 inhibitors were randomised to tadalafil 5mg once a day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was 68% for tadalafil patients compared to 52% for patients on placebo.</p><p><strong>Paediatric population</strong></p><p>A single study has been performed in paediatric patients with Duchenne Muscular Dystrophy (DMD) in which no evidence of efficacy was seen. The randomised, double&ndash;blind, placebo&ndash;controlled, parallel, 3&ndash;arm study of tadalafil was conducted in 331 boys aged 7&ndash;14 years with DMD receiving concurrent corticosteroid therapy. The study included a 48&ndash;week double-blind period where patients were randomised to tadalafil 0.3 mg/kg, tadalafil 0.6 mg/kg, or placebo daily. Tadalafil did not show efficacy in slowing the decline in ambulation as measured by the primary 6 minute walk distance (6MWD) endpoint: least squares (LS) mean change in 6MWD at 48 weeks was &ndash;51.0 meters (m) in the placebo group, compared with &ndash;64.7 m in the tadalafil 0.3 mg/kg group (p = 0.307) and &ndash;59.1 m in the tadalafil 0.6 mg/kg group (p = 0.538). In addition, there was no evidence of efficacy from any of the secondary analyses performed in this study. The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events (AEs) expected in a paediatric DMD population receiving corticosteroids.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma concentration (C<sub>max</sub>) is achieved at a median time of 2 hours after dosing. Absolute bioavailability of tadalafil following oral dosing has not been determined.</p><p>The rate and extent of absorption of tadalafil are not influenced by food, thus tadalafil may be taken with or without food. The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Distribution</u></strong></p><p>The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein binding is not affected by impaired renal function.</p><p>Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.</p><p><strong><u>Biotransformation</u></strong></p><p>Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed metabolite concentrations.</p><p><strong><u>Elimination</u></strong></p><p>The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy subjects.</p><p>Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).</p><p><strong><u>Linearity/Non-Linearity</u></strong></p><p>Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state plasma concentrations are attained within 5 days of once daily dosing.</p><p>Pharmacokinetics determined with a population approach in patients with erectile dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.</p><p><strong><u>Special Populations</u></strong></p><p><strong>Elderly</strong></p><p>Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not clinically significant and does not warrant a dose adjustment.</p><p><strong>Renal Insufficiency</strong></p><p>In clinical pharmacology studies using single dose tadalafil (5 to 20mg), tadalafil exposure (AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate (creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal disease on dialysis. In haemodialysis patients, C<sub>max</sub>&nbsp;was 41% higher than that observed in healthy subjects. Haemodialysis contributes negligibly to tadalafil elimination.</p><p><strong>Hepatic Insufficiency </strong></p><p>Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is administered. There is limited clinical data on the safety of tadalafil in patients with severe hepatic insufficiency (Child-Pugh class C). If tadalafil is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of once-a-day dosing of tadalafil to patients with hepatic impairment. If tadalafil is prescribed once-a-day, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.</p><p><strong>Patients with Diabetes</strong></p><p>Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.</p><p>There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated free drug at this dose was approximately 18-times the human AUC at a 20 mg dose.</p><p>There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:492px"><tbody><tr><td style="vertical-align:top"><table border="0" cellspacing="0" cellpadding="0" style="width:492px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>For Core:</strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Lactose monohydrate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Microcrystalline cellulose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium lauryl sulphate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Hydroxy propyl cellulose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Croscarmellose sodium</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Magnesium stearate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Purified water **</li></ol></td></tr><tr><td style="vertical-align:top"><p><strong>For Coating:</strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Hypromellose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Triacetin</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Talc fine powder</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Titanium dioxide</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Lactose monohydrate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Iron oxide yellow</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Purified water **</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Absolute alcohol **</li></ol></td></tr></tbody></table><p><strong><u>Note:</u></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:492px"><tbody><tr><td style="vertical-align:top"><p>**</p></td><td style="vertical-align:top"><p>This will not appear in the final product.</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 1 Tablet:</strong> 1 Tablet in Alu-PVC/ PVDC blister, packed in a printed carton along with a leaflet.</p><p>&sect; <strong>Pack of 4 Tablets:</strong> 4 Tablets in Alu-PVC/ PVDC blister, 1 blister is packed in a printed carton along with a leaflet.</p><p>&sect; <strong>Pack of 12 Tablets: </strong>4 Tablets in Alu-PVC/ PVDC blister, 3 blisters is packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30. December. 2020

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>